



Commercial/Healthcare Exchange PA Criteria

Effective: November 2018

Prior Authorization: Steroid - Beta Agonist Combo Inhalers

Products Affected: AirDuo RespiClick (fluticasone and salmeterol) inhalation; AirDuo Digihaler (fluticasone and salmeterol) inhalation; Fluticasone/Salmeterol HFA inhalation

Medication Description: Fluticasone/salmeterol is a combination of an inhaled corticosteroid (ICS), fluticasone, and a long-acting beta-agonist (LABA), salmeterol. The combination is used for maintenance therapy of asthma.

Covered Uses: Asthma

Exclusion Criteria: Status asthmaticus or other acute episodes of asthma

Required Medical Information:

1. Diagnosis
2. Previous medications tried and failed

Age Restrictions: 12 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

1. Patient has a diagnosis of Asthma; AND
2. Patient has had a documented trial and failure of at least TWO of the following medications:
 - A. Advair HFA
 - B. Breo Ellipta
 - C. Dulera
 - D. Symbicort

References:

1. Product Information: AIRDUO(R) DIGIHALER(TM) inhalation powder, fluticasone propionate salmeterol inhalation powder. Teva Respiratory, LLC (per manufacturer), Frazer, PA, 2019.

Last Res. September 2020

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/2018
2	Update	Removed affected products from existing CCI policies; Adopted EH template; specified criteria;	All	1/13/2020
3	Update	Added AirDuo Digihaler	Products Affected	9/17/2020